Catching Up With Fate: Deal With CRISPR Brings Nkarta Up In NK Cell Race
Partnership Seen As Validating CD70 As Antigen Target
The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.
You may also be interested in...
NKX101 in acute myeloid leukemia and NKX019 in non-Hodgkin’s lymphoma showed high complete response rates, but without the toxicity associated with CAR-Ts.
While the data are early, they have also generated positive views toward the company’s pipeline ahead of an anticipated CAR-NK data announcement at its investor meeting.
Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.